Marksans Pharma Ltd on Wednesday said it has received final approval from the US health regulator for its generic version of Benzonatate capsules indicated for treatment of persistent cough, bronchitis, pneumonia or other lung infections.The approval by the US Food and Drug Administration (USFDA) is for the company's abbreviated new drug application (ANDA) for Benzonatate capsules of strengths 100 mg and 200 mg, Marksans Pharma said in a regulatory filing.This product is bioequivalent and therapeutically eq ...

Novo Nordisk rose as much as 4% after England's drug price regulator recommended the use of its best-selling drug Wegovy to prevent heart attacks and strokes. Wegovy is mainly a weight loss treatment but it is also approved for reducing the risk of major cardiovascular events in people living with overweight or obesity. The new recommendation the National Institute for Health and Care Excellence (NICE), England's drug price regulator, will significantly expand access to Wegovy on the country's National Heal ...

PresentationGood day, and thank you for standing by. Welcome to the ORIC Pharma Update Conference Call. [Operator Instructions]. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Dominic Piscitelli. Please go ahead, sir.Dominic PiscitelliChief Financial Officer Welcome to the ORIC Pharmaceuticals rinzimetostat dose optimization data update call. Earlier today, we issued a press release highlighting new clinical data and details f ...

Fear is in the air. Sure, the S&P 500 (^GSPC +2.91%) is holding up pretty well in the face of significant uncertainty. However, implied volatility has risen sharply in recent weeks.Should investors stay away from all stocks with a 10-foot pole? Nope. Here are three dividend stocks you can buy with no hesitation. 1. Johnson & JohnsonJohnson & Johnson (JNJ +0.83%) remains a favorite among investors who want to sleep at night without worrying about their portfolios. The healthcare giant has an AAA credit ratin ...

Oil has fallen below $100 per barrel and Asian shares are sharply higher, after U.S. stocks soared to their best day in almost a year over renewed hopes that the Iran war could soon endA currency trader reacts near a screen showing the Korea Composite Stock Price Index (KOSPI), right, and the foreign exchange rate between U.S. dollar and South Korean won at the foreign exchange dealing room of the Hana Bank headquarters in Seoul, South Korea, Wednesday, April 1, 2026. (AP Photo/Ahn Young-joon)HONG KONG -- O ...

以下文章来源于凤凰网财经 ，作者公司研究院 凤凰网财经 . 将投中网设为"星标⭐"，第一时间收获最新推送 这款药刚上市的时候，简直是"印钞机"一样的存在。 来源丨 凤凰网财经 你好，我们是凤凰网财经，全球华人都在看的财经公众号，传播最有价值的财经报道，你值得关注！欢迎访问：http://finance.ifeng.com/ 提起白云山，很多人可能先想到它的板蓝根、复方丹参片，但其实在过去很长一段时间里，真正让白云山赚得盆满钵满的，是一款叫"金戈"的药，也就 是常说的国产伟哥。 这款药刚上市的时候，简直是"印钞机"一样的存在，可最近两年，它却明显"卖不动"了。 曾躺着就能赚钱，现在连续两年下滑 金戈的崛起，其实很会"踩时机"。 2014 年之前，国内治疗男性 ED （勃起功能障碍）的药，基本被进口的万艾可（伟哥）垄断，价格贵得离谱，一片就要一百多块，很多人想买却舍不 得。 就在这一年，万艾可的专利到期了，白云山抓住机会，推出了国产仿制药金戈，价格直接降到了万艾可的三分之一。 效果差不多，价格却便宜一大半，老百姓自然愿意买。 刚上市的第一年，金戈只卖了 292 万片，不算多，但第二年就迎来了爆发，一下子卖到了 1 ...

Core Viewpoint - Kahn Swick & Foti, LLC is investigating the proposed sale of Apellis Pharmaceuticals, Inc. to Biogen Inc. to assess the adequacy of the price and process involved in the transaction [1]. Summary by Relevant Sections - **Proposed Transaction Details** - Apellis shareholders are set to receive $41.00 per share in cash along with a nontransferable contingent value right for two additional payments of $2.00 per share, contingent on meeting specific annual global net sales thresholds for SYFOVRE [1]. - **Investigation Purpose** - The investigation aims to determine whether the proposed consideration undervalues Apellis Pharmaceuticals and whether the process leading to this valuation was adequate [1]. - **Contact Information for Investors** - Investors who believe the transaction undervalues the company can contact Kahn Swick & Foti, LLC for further discussion regarding their legal rights [2].

Shares of Centessa Pharmaceuticals (CNTA +43.80%) surged on Tuesday after the drugmaker struck a deal to be acquired by Eli Lilly (LLY +3.55%) for as much as $7.8 billion. An enticing offer for Centessa's investorsUnder the terms of the deal, Lilly would purchase Centessa for $38 per share in cash. That's a premium of nearly 38% to the healthcare stock's closing price on Monday.Centessa's shareholders would also receive a non-transferrable contingent value right, which could be valued at up to $9 per share ...

1 Apr 2026 CMB International Global Markets | Equity Research | Company Update 3SBio (1530 HK) 3SBio (1530 HK) - Short-term Short-term pressure on product sales; ASCO 2026 in focus 3SBio reported revenue of RMB17.7bn (+94.3% YoY) in 2025, driven by the RMB9.4bn out-licensing income from Pfizer for 707. However, product sales declined by 10.3% YoY to RMB8.0bn amid China's VBP and reimbursement control headwinds. Excluding the licensing income, R&D and administrative expense ratios rose ~4ppts and ~2ppts, res ...

In this article, we will look at the 7 Best Pharma Stocks to Invest In Now.On March 24, Scott Chronert, Citi, appeared on CNBC’s ‘Closing Bell’ to talk about the market and whether it is time to get into equity markets. He said that there are two stories in the market right now, with the first being on a short-term basis. Positioning had been skewed to the negative over the past three weeks as the Iran conflict unfolded. Therefore, on a short-term basis, any alleviation of the risk around the duration of th ...